MacroGenics Inc. (MGNX), which has a diverse portfolio of oncology product candidates, is poised for multiple pipeline advancements this year.
The lead drug candidate is Vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a protein widely expressed by several different tumor types.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com